



Ironwood Pharmaceuticals to Host First Quarter 2012 Investor Update Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Ironwood Pharmaceuticals, Inc.](http://www.ironwoodpharma.com) (NASDAQ: IRWD) today announced it will host its first quarter 2012 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, May 1, 2012. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using the conference ID number 74951581. To access the webcast, please visit the investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting May 1, 2012 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on May 8, 2012. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 74951581. The archived webcast will be available on Ironwood's website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. The efficacy portion of linaclotide's development program has been completed and supports the recently submitted NDA submission for both indications, as well as the MAA submission in Europe for the IBS-C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

Ironwood Pharmaceuticals, Inc.

Corporate Inquiries:

Susan Brady, 617-621-8304

Corporate Communications

sbrady@ironwoodpharma.com

or

Investor Inquiries:

Meredith Kaya, 617-374-5082

Investor Relations

mkaya@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

News Provided by Acquire Media